XML 240 R38.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Segment Information (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Segment Reporting, Measurement Disclosures [Abstract] |
Detailed Segment Data | Detailed segment data for the years ended December 31 is as follows ($ in millions):
| Biotechnology |  | Life Sciences |  | Diagnostics |  |  |  | Other (a) |  | Total Company
Year Ended December 31, 2024 |  |  |  |  |  |  |  |  |  |  |
Sales (GAAP) | $ | 6,759 |  |  | $ | 7,329 |  |  | $ | 9,787 |  |  |  |  | $ | — |  |  | $ | 23,875 |
Less: |  |  |  |  |  |  |  |  |  |  |
Depreciation | (151) |  |  | (167) |  |  | (394) |  |  |  |  | (9) |  |  | (721) |
Amortization of intangible assets | (863) |  |  | (576) |  |  | (192) |  |  |  |  | — |  |  | (1,631) |
Impairments(b) | — |  |  | (222) |  |  | (43) |  |  |  |  | — |  |  | (265) |
Other segment expenses(c) | (4,060) |  |  | (5,485) |  |  | (6,533) |  |  |  |  | (317) |  |  | (16,395) |
Operating profit | $ | 1,685 |  |  | $ | 879 |  |  | $ | 2,625 |  |  |  |  | $ | (326) |  |  | $ | 4,863 |
Year Ended December 31, 2023 |  |  |  |  |  |  |  |  |  |  |
Sales (GAAP) | $ | 7,172 |  |  | $ | 7,141 |  |  | $ | 9,577 |  |  |  |  | $ | — |  |  | $ | 23,890 |
Less: |  |  |  |  |  |  |  |  |  |  |
Depreciation | (162) |  |  | (129) |  |  | (379) |  |  |  |  | (5) |  |  | (675) |
Amortization of intangible assets | (864) |  |  | (429) |  |  | (198) |  |  |  |  | — |  |  | (1,491) |
Impairments(b) | (54) |  |  | — |  |  | (23) |  |  |  |  | — |  |  | (77) |
Other segment expenses(c) | (4,183) |  |  | (5,374) |  |  | (6,571) |  |  |  |  | (317) |  |  | (16,445) |
Operating profit | $ | 1,909 |  |  | $ | 1,209 |  |  | $ | 2,406 |  |  |  |  | $ | (322) |  |  | $ | 5,202 |
Year Ended December 31, 2022 |  |  |  |  |  |  |  |  |  |  |
Sales (GAAP) | $ | 8,758 |  |  | $ | 7,036 |  |  | $ | 10,849 |  |  |  |  | $ | — |  |  | $ | 26,643 |
Less: |  |  |  |  |  |  |  |  |  |  |
Depreciation | (190) |  |  | (112) |  |  | (387) |  |  |  |  | (9) |  |  | (698) |
Amortization of intangible assets | (812) |  |  | (419) |  |  | (203) |  |  |  |  | — |  |  | (1,434) |
Other segment expenses(c) | (4,748) |  |  | (5,091) |  |  | (6,823) |  |  |  |  | (313) |  |  | (16,975) |
Operating profit | $ | 3,008 |  |  | $ | 1,414 |  |  | $ | 3,436 |  |  |  |  | $ | (322) |  |  | $ | 7,536 |
(a) Other consists of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance. (b) For information on the impairments, refer to Note 10. (c) Other segment expenses for each reportable segment include cost of sales, selling general and administrative expenses, research and development (“R&D”) expenses, excluding depreciation, amortization of intangible assets and impairments. Included within these categories of expenses are overhead expenses, stock compensation expense, restructuring charges and allocated corporate expenses. The following table presents additional detailed segment data for the years ended December 31 ($ in millions):
| 2024 |  | 2023 |  | 2022
Identifiable assets: |  |  |  |  |
Biotechnology | $ | 34,605 |  |  | $ | 37,421 |  |  | $ | 37,536 |
Life Sciences | 23,211 |  |  | 23,730 |  |  | 17,572 |
Diagnostics | 14,204 |  |  | 14,552 |  |  | 14,722 |
Other | 5,522 |  |  | 8,785 |  |  | 9,739 |
Discontinued operations | — |  |  | — |  |  | 4,781 |
Total | $ | 77,542 |  |  | $ | 84,488 |  |  | $ | 84,350 |
Capital expenditures, gross: |  |  |  |  |
Biotechnology | $ | 447 |  |  | $ | 417 |  |  | $ | 405 |
Life Sciences | 391 |  |  | 320 |  |  | 325 |
Diagnostics | 550 |  |  | 546 |  |  | 382 |
Other | 4 |  |  | 100 |  |  | 6 |
Total | $ | 1,392 |  |  | $ | 1,383 |  |  | $ | 1,118 |
Schedule of Operations in Geographical Areas | Operations in Geographical Areas:
| Year Ended December 31
($ in millions) | 2024 |  | 2023 |  | 2022
Sales: |  |  |  |  |
United States | $ | 9,927 |  |  | $ | 9,579 |  |  | $ | 11,289 |
China | 2,805 |  |  | 3,143 |  |  | 3,611 |
All other (each country individually less than 5% of total sales) | 11,143 |  |  | 11,168 |  |  | 11,743 |
Total | $ | 23,875 |  |  | $ | 23,890 |  |  | $ | 26,643 |
Property, plant and equipment, net: |  |  |  |  |
United States | $ | 2,585 |  |  | $ | 2,304 |  |  | $ | 1,839 |
United Kingdom | 519 |  |  | 371 |  |  | 239 |
Sweden | 384 |  |  | 425 |  |  | 429 |
Germany | 251 |  |  | 238 |  |  | 204 |
All other (each country individually less than 5% of total property, plant and equipment, net) | 1,251 |  |  | 1,215 |  |  | 998 |
Total | $ | 4,990 |  |  | $ | 4,553 |  |  | $ | 3,709 |

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingMeasurementDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration